The tumor suppressor maspin mediates E2F1-induced sensitivity of cancer cells to chemotherapy

Molecular Cancer Research

Volumn 8, Issue 3, 2010, Pages 363-372

  Shachar, Berta Ben ^a   Feldstein, Orit ^a   Hacohen, Dalia ^a   Ginsberg, Doron ^a  

^a BAR ILAN UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; MESSENGER RNA; PROTEIN P53; SERINE PROTEINASE INHIBITOR; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR E2F1;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE REGULATION; CHEMOSENSITIZATION; CONTROLLED STUDY; DRUG POTENTIATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; E2F1 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; RNA INTERFERENCE; RNA, MESSENGER; SERPINS; TUMOR SUPPRESSOR PROTEINS;

EID: 77949693603     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-09-0137     Document Type: Article

References (53)

1. DeGregori J, Johnson DG. Distinct and overlapping roles for E2F family members in transcription, proliferation and apoptosis. Curr Mol Med 2006;6:739-48.
2. Polager S, Ginsberg D. E2F - at the crossroads of life and death. Trends Cell Biol 2008;18:528-35.
3. Johnson DG, Degregori J. Putting the oncogenic and tumor suppressive activities of E2F into context. Curr Mol Med 2006;6: 731-8.
4. Phillips AC, Vousden KH. E2F-1 induced apoptosis. Apoptosis 2001; 6:173-82.
5. Ginsberg D. E2F1 pathways to apoptosis. FEBS Lett 2002;529: 122-5.
6. Field SJ, Tsai FY, Kuo F, et al. E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell 1996;85:549-61.
7. Tsai KY, Hu Y, Macleod KF, Crowley D, Yamasaki L, Jacks T. Mutation of E2f-1 suppresses apoptosis and inappropriate S phase entry and extends survival of Rb-deficient mouse embryos. Mol Cell 1998; 2:293-304.
8. Ziebold U, Reza T, Caron A, Lees AJ. E2F3 contributes both to the inappropriate proliferation and to the apoptosis arising in Rb mutant embryos. Genes Dev 2001;15:386-91.
9. Bates S, Phillips AC, Clark PA, Stott F, Peters G, Ludwig RL, Vousden KH. p14ARF links the tumour suppressors RB and p53 [letter]. Nature 1998;395:124-5.
10. Robertson KD, Jones PA. The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53. Mol Cell Biol 1998;18:6457-73.
11. Irwin M, Marin MC, Phillips AC, et al. Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature 2000;407:645-8.
12. Stiewe T, Putzer BM. Role of the p53-homologue p73 in E2F1-induced apoptosis. Nat Genet 2000;26:464-9.
13. Moroni MC, Hickman ES, Denchi EL, et al. Apaf-1 is a transcriptional target for E2F and p53. Nat Cell Biol 2001;3:552-8.
14. Furukawa Y, Nishimura N, Satoh M, et al. Apaf-1 is a mediator of E2F-1-induced apoptosis. J Biol Chem 2002;30:30.
15. Nahle Z, Polakoff J, Davuluri RV, et al. Direct coupling of the cell cycle and cell death machinery by E2F. Nat Cell Biol 2002;4:859-64.
16. Hershko T, Ginsberg D. Up-regulation of Bcl-2 homology 3 (BH3)-only proteins by E2F1 mediates apoptosis. J Biol Chem 2004; 279:8627-34.
17. Dick FA, Dyson N. pRB contains an E2F1-specific binding domain that allows E2F1-induced apoptosis to be regulated separately from other E2F activities. Mol Cell 2003;12:639-49.
18. Lin WC, Lin FT, Nevins JR. Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation. Genes Dev 2001;15:1833-44.
19. Stevens C, Smith L, La Thangue NB. Chk2 activates E2F-1 in response to DNA damage. Nat Cell Biol 2003;5:401-9.
20. Pediconi N, Ianari A, Costanzo A, et al. Differential regulation of E2F1 apoptotic target genes in response to DNA damage. Nat Cell Biol 2003;19:19.
21. Ma Y, Cress WD, Haura EB. Flavopiridol-induced apoptosis is mediated through up-regulation of E2F1 and repression of Mcl-1. Mol Cancer Ther 2003;2:73-81.
22. Urist M, Tanaka T, Poyurovsky MV, Prives C. p73 induction after DNA damage is regulated by checkpoint kinases Chk1 and Chk2. Genes Dev 2004;18:3041-54.
23. Ambrosini G, Sambol EB, Carvajal D, Vassilev LT, Singer S, Schwartz GK. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1. Oncogene 2007;26:3473-81.
24. Nip J, Strom DK, Fee BE, Zambetti G, Cleveland JL, Hiebert SW. E2F-1 cooperates with topoisomerase II inhibition and DNA damage to selectively augment p53-independent apoptosis. Mol Cell Biol 1997;17:1049-56.
25. Banerjee D, Schnieders B, Fu JZ, Adhikari D, Zhao SC, Bertino JR. Role of E2F-1 in chemosensitivity. Cancer Res 1998;58:4292-6.
26. Meng RD, Phillips P, El-Deiry WS. p53-independent increase in E2F-1 expression enhances the cytotoxic effects of etoposide and of Adriamycin. Int J Oncol 1999;14:5-14.
27. Dong YB, Yang HL, Elliott MJ, McMasters KM. Adenovirus-mediated E2F-1 gene transfer sensitizes melanoma cells to apoptosis induced by topoisomerase II inhibitors. Cancer Res 2002;62: 1776-83.
28. Hao H, Dong YB, Bowling MT, Zhou HS, McMasters KM. Alteration of gene expression in melanoma cells following combined treatment with E2F-1 and doxorubicin. Anticancer Res 2006;26: 1947-56.
29. Elliott MJ, Farmer MR, Atienza C, Jr., et al. E2F-1 gene therapy induces apoptosis and increases chemosensitivity in human pancreatic carcinoma cells. Tumour Biol 2002;23:76-86.
30. Berkovich E, Ginsberg D. ATM is a target for positive regulation by E2F-1. Oncogene 2003;22:161-7.
31. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002;296: 550-3.
32. Vigo E, Muller H, Prosperini E, Hateboer G, Cartwright P, Moroni MC, Helin K. CDC25A phosphatase is a target of E2F and is required for efficient E2F-induced S phase. Mol Cell Biol 1999;19:6379-95.
33. Carrle D, Bielack SS. Current strategies of chemotherapy in osteosarcoma. Int Orthop 2006;30:445-51.
34. Khalkhali-Ellis Z. Maspin: the new frontier. Clin Cancer Res 2006;12: 7279-83.
35. Wu X, Levine AJ. p53 and E2F-1 cooperate to mediate apoptosis. Proc Natl Acad Sci U S A 1994;91:3602-6.
36. Oren M. Decision making by p53: life, death and cancer. Cell Death Differ 2003;10:431-42.
37. Dong YB, Yang HL, McMasters KM. E2F-1 overexpression sensitizes colorectal cancer cells to camptothecin. Cancer Gene Ther 2003;10: 168-78.
38. Gomez-Manzano C, Lemoine MG, Hu M, et al. Adenovirally-mediated transfer of E2F-1 potentiates chemosensitivity of human glioma cells to temozolomide and BCNU. Int J Oncol 2001;19: 359-65.
39. Li X, Chen D, Yin S, et al. Maspin augments proteasome inhibitor-induced apoptosis in prostate cancer cells. J Cell Physiol 2007; 212:298-306.
40. Hershko T, Korotayev K, Polager S, Ginsberg D. E2F1 modulates p38 MAPK phosphorylation via transcriptional regulation of ASK1 and Wip1. J Biol Chem 2006;281:31309-16.
41. Zou Z, Gao C, Nagaich AK, et al. p53 regulates the expression of the tumor suppressor gene maspin. J Biol Chem 2000;275:6051-4.
42. Domann FE, Rice JC, Hendrix MJ, Futscher BW. Epigenetic silencing of maspin gene expression in human breast cancers. Int J Cancer 2000;85:805-10.
43. Zou Z, Anisowicz A, Hendrix MJ, et al. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 1994;263:526-9.
44. Maass N, Biallek M, Rosel F, et al. Hypermethylation and histone deacetylation lead to silencing of the maspin gene in human breast cancer. Biochem Biophys Res Commun 2002;297:125-8.
45. Zhang M, Volpert O, Shi YH, Bouck N. Maspin is an angiogenesis inhibitor. Nat Med 2000;6:196-9.
46. Schaefer JS, Zhang M. Role of maspin in tumor metastasis and angiogenesis. Curr Mol Med 2003;3:653-8.
47. Jiang N, Meng Y, Zhang S, Mensah-Osman E, Sheng S. Maspin sensitizes breast carcinoma cells to induced apoptosis. Oncogene 2002; 21:4089-98.
48. Liu J, Yin S, Reddy N, Spencer C, Sheng S. Bax mediates the apoptosis-sensitizing effect of maspin. Cancer Res 2004;64:1703-11.
49. Tahmatzopoulos A, Sheng S, Kyprianou N. Maspin sensitizes prostate cancer cells to doxazosin-induced apoptosis. Oncogene 2005; 24:5375-83.
50. McKenzie S, Sakamoto S, Kyprianou N. Maspin modulates prostate cancer cell apoptotic and angiogenic response to hypoxia via targeting AKT. Oncogene 2008.
51. Dietmaier W, Bettstetter M, Wild PJ, et al. Nuclear Maspin expression is associated with response to adjuvant 5-fluorouracil based chemotherapy in patients with stage III colon cancer. Int J Cancer 2006;118: 2247-54.
52. Marioni G, Koussis H, Gaio E, et al. MASPIN's prognostic role in patients with advanced head and neck carcinoma treated with primary chemotherapy (carboplatin plus vinorelbine) and radiotherapy: preliminary evidence. Acta Otolaryngol 2008:1-7.
53. Klasa-Mazurkiewicz D, Narkiewicz J, Milczek T, Lipinska B, Emerich J. Maspin overexpression correlates with positive response to primary chemotherapy in ovarian cancer patients. Gynecol Oncol 2009; 113:91-98.